A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings

The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).

Study Overview

• Status: Completed
• Conditions: Hepatitis C Virus
• Intervention / Treatment: Drug: No intervention

Detailed Description

This is a multicenter, observational (a study in which the investigators/ physicians observe the patients and measure their outcomes), prospective study (a study in which the patients are identified and then followed forward in time for the outcome of the study) designed to reflect routine clinical practice. Approximately 300 Hepatitis C virus (HCV) infected patients who are prescribed simeprevir by their health care provider as part of their routine HCV treatment regimen, inclusive of patients who have been treated with a simeprevir-based therapy for less than or equal to (<=) 28 days will be enrolled in this and observed to evaluate the effectiveness of a simeprevir. Practice setting features will be documented at the initiation of the study by each participating site. The decision of patients to participate in this study will in no way impact upon the standard of care that they are receiving. All treatment decisions will be made at the discretion of the health care provider. Safety assessments will include assessment of adverse events, and clinical laboratory parameters (hematology, clotting tests, human immunodeficiency virus tests, chemistry, and liver function tests). The maximum study duration for each patient will be approximately 2 years.

• Study Type: Observational
• Enrollment (Actual): 315

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States
  • California
    • Bakersfield, California, United States
    • Beverly Hills, California, United States
    • Los Angeles, California, United States
  • Florida
    • Daytona Beach, Florida, United States
    • Deland, Florida, United States
    • Miami, Florida, United States
    • Tampa, Florida, United States
    • West Palm Beach, Florida, United States
  • Kentucky
    • Crestview Hills, Kentucky, United States
  • Maryland
    • Baltimore, Maryland, United States
  • Massachusetts
    • Springfield, Massachusetts, United States
  • New Jersey
    • Newark, New Jersey, United States
    • Vineland, New Jersey, United States
  • New York
    • Brooklyn, New York, United States
    • Flushing, New York, United States
    • New York, New York, United States
    • Ny, New York, United States
  • North Carolina
    • Durham, North Carolina, United States
    • Fayetteville, North Carolina, United States
    • Rocky Mount, North Carolina, United States
    • Statesville, North Carolina, United States
    • Winston Salem, North Carolina, United States
  • Ohio
    • Cincinnati, Ohio, United States
  • Pennsylvania
    • Doylestown, Pennsylvania, United States
    • Philadelphia, Pennsylvania, United States
  • Tennessee
    • Nashville, Tennessee, United States
  • Texas
    • Austin, Texas, United States
    • Dallas, Texas, United States
    • Fort Worth, Texas, United States
    • Houston, Texas, United States
  • Utah
    • Murray, Utah, United States
  • Virginia
    • Norfolk, Virginia, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Hepatitis C virus (HCV) infected patients receiving simeprevir.

Description

Inclusion Criteria:

• Patients who have genotype 1 chronic hepatitis C infection
• Hepatitis C virus (HCV) ribonucleic acid (RNA) test result above the limit of quantification before initiation of simeprevir-based therapy
• Health care provider decision to treat patient with a simeprevir-based therapy, inclusive of patients who have been treated with a simeprevir-based therapy for less than or equal to (<=) 28 days will be enrolled into the study
• Prior HCV treatment must be completed more than 3 months before initiation of simeprevir-based therapy
• In the opinion of the health care provider, the patient will attend routine standard of care visits, either at enrolled site or by virtual/telemedicine

Exclusion Criteria:

• Non-genotype 1 HCV infected patients
• Absolute contraindication to any component of prescribed HCV treatment per prescribing information
• Patient is currently enrolled in an interventional study
• Past use of an HCV direct-acting antiviral therapy
• Any investigational drug use within 30 days before initiation of simeprevir-based therapy

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hepatitis C virus infected patients receiving simeprevir	Drug: No intervention; This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients who Achieve Sustained Virologic Response(SVR)	SVR is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) undetectable at least 12 weeks after the actual end of all HCV treatment. Actual end of treatment will be determined by health care provider.	12 weeks after the actual end of treatment (an expected average of up to 2 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of Prognostic Factors of Virologic Response	Prognostic factors of virologic response includes patient and disease characteristics, treatment paradigm, Rapid Virologic Response (RVR), and select practice setting features. Actual end of treatment will be determined by health care provider.	12 weeks after the actual end of treatment (an expected average of up to 2 years)
Total duration of therapy	Actual end of treatment will be determined by health care provider.	Up to actual end of treatment (an expected average of up to 2 years)
Number of Patients who Discontinue Therapy by reason	Actual end of treatment will be determined by health care provider.	Up to actual end of treatment (an expected average of up to 2 years)
Number of Patients who Achieve Rapid Virologic Response (RVR)	RVR is defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 4.	Week 4
Number of Patients who Achieve Sustained Virologic Response(SVR) Among Participants who Achieve Rapid Virologic Response (RVR)	SVR is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) undetectable at least 12 weeks after the actual end of all HCV treatment. RVR is defined as undetectable HCV RNA at Week 4. Actual end of treatment will be determined by health care provider. Actual end of treatment will be determined by health care provider.	12 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients who Achieve Sustained Virologic Response(SVR) According to Patient Demographics, Baseline Disease Characteristics, Treatment Paradigm, and Select Practice Setting Features	Actual end of treatment will be determined by health care provider.	12 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients With On-treatment Virologic Failure	On-treatment virologic failure is defined as a confirmed increase of >1 log10 IU/mL in hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached, or a confirmed HCV RNA level of >100 IU/mL in patients whose HCV RNA had previously been <25 IU/mL. Actual end of treatment will be determined by health care provider.	Up to actual end of treatment (an expected average of up to 2 years)
Number of Patients With Viral Relapse	Viral Relapse is defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) after concluding treatment with undetectable HCV RNA. Actual end of treatment will be determined by health care provider.	Up to actual end of treatment (an expected average of up to 2 years)
Number of Patients With Adverse Events by Grade and Causality	Actual end of treatment will be determined by health care provider.	Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients With Changes in Clinical Laboratory Parameters by Grade and Causality	Actual end of treatment will be determined by health care provider.	Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients With Adverse Event Determined to be Related to Simeprevir	Actual end of treatment will be determined by health care provider.	Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients With Serious Adverse Event	Actual end of treatment will be determined by health care provider.	Up to 24 weeks after the actual end of treatment (an expected average of up to 2 years)
Number of Patients who Develop Mutations at the Time of Virologic Failure	Actual end of treatment will be determined by health care provider.	Up to actual end of treatment (an expected average of up to 2 years)

Collaborators and Investigators

• Sponsor: Janssen Scientific Affairs, LLC

Study record dates

Study Major Dates

• Study Start: February 1, 2014
• Primary Completion (Actual): November 1, 2015
• Study Completion (Actual): January 1, 2016

Study Registration Dates

• First Submitted: February 18, 2014
• First Submitted That Met QC Criteria: April 1, 2014
• First Posted (Estimate): April 4, 2014

Study Record Updates

• Last Update Posted (Estimate): February 22, 2016
• Last Update Submitted That Met QC Criteria: February 19, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Simeprevir; Hepatitis C virus; Sustained virologic response; Ribonucleic acid
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis; Hepatitis A; Hepatitis C
• Other Study ID Numbers: CR101973; TMC435HPC4003 (Other Identifier: Janssen Scientific Affairs, LLC)